U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07375212) titled 'VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure' on July 16, 2025.
Brief Summary: This trial is seeking to determine whether a single 4mg intranasal dose of bumetanide acutely reduces pulmonary artery pressure and blood volume in the outpatient setting for patients with heart failure and an implanted device for remote patient monitoring (i.e. Cordella or CardioMEMS).
Study Start Date: Jan. 21
Study Type: INTERVENTIONAL
Condition:
Heart Failure Congestive
Intervention:
DRUG: Bumetanide, intranasal 4mg
Intranasal route of administration for 4mg of bumetanide
Recruitment Status: WITHDRAWN
Sponsor:...